Analyzing tumor samples from patients with kidney and bladder cancers
Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kinetics in Patients With Renal Cell Carcinoma (RCC) and Urothelial Carcinoma (UC) Treated With Immune Checkpoint Blockade (ICB)
This study looks at tumor samples from kidney and bladder cancer patients to see how their tumors change before and after treatment, especially in those who received a specific immune therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 16 (estimated) |
| Sex | All |
| Sponsor | Fox Chase Cancer Center Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT03291028 on ClinicalTrials.gov |
What this trial studies
This observational study examines tumor samples from patients diagnosed with renal cell carcinoma and urothelial carcinoma who have undergone surgical removal of lesions. It focuses on comparing pre-treatment and metastatic samples to identify genomic changes associated with metastasis, particularly in patients who received immune checkpoint blockade targeting PD1. Additionally, it includes a comparator group of patients who underwent metastasectomy without prior ICB treatment to assess differences in tumor behavior and resistance development.
Who should consider this trial
Good fit: Ideal candidates include patients with renal cell carcinoma or urothelial carcinoma who have previously benefited from immune checkpoint blockade but later developed new lesions.
Not a fit: Patients with tumor types other than renal cell carcinoma or urothelial carcinoma are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of tumor evolution and resistance mechanisms in kidney and bladder cancers, potentially leading to improved treatment strategies.
How similar studies have performed: Similar studies have shown promise in understanding tumor resistance mechanisms, but this specific comparative approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Eligible patients will include retrospectively identified patients with RCC or UC who have received treatment with ICB and achieved clinical benefit but subsequently developed a solitary new/progressive lesion that was removed surgically. Patients with other tumor types who otherwise meet criteria may be included at a later time * Additionally, a group of patients with RCC who have undergone a metastasectomy but who did not receive treatment with ICB will be identified. These patients may be approached for study participation to serve as a comparator group Exclusion Criteria: \-
Where this trial is running
Philadelphia, Pennsylvania
- Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: Matthew Zibelman, MD
- Email: matthew.zibelman@fccc.edu
- Phone: 215 214 1515
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.